Dual-drug loaded nanomedicine hydrogel as a therapeutic platform to target both residual glioblastoma and glioma stem cells.
Gemcitabine
Glioblastoma
Glioma stem cells
Hydrogel
Local delivery
Salinomycin
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
25 Nov 2022
25 Nov 2022
Historique:
received:
29
06
2022
revised:
19
10
2022
accepted:
22
10
2022
pubmed:
8
11
2022
medline:
16
11
2022
entrez:
7
11
2022
Statut:
ppublish
Résumé
Glioblastoma (GBM) recurrences are inevitable, and mainly originate from residual tumor cells and the presence of glioma stem cells (GSC) around the resection cavity borders. We previously showed that the local treatment of GBM with nanomedicine-based Lauroyl-gemcitabine lipid nanocapsules (GemC
Identifiants
pubmed: 36341916
pii: S0378-5173(22)00896-1
doi: 10.1016/j.ijpharm.2022.122341
pii:
doi:
Substances chimiques
Hydrogels
0
Lipids
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122341Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.